CSCO BC Guidelines | Prof. Ying Yan: Precision Diagnosis and Tailored Therapy — Treatment Updates for HER2-Low and Ultra-Low Breast Cancer

CSCO BC Guidelines | Prof. Ying Yan: Precision Diagnosis and Tailored Therapy — Treatment Updates for HER2-Low and Ultra-Low Breast Cancer

The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, introduced significant updates to the 2025 edition of the CSCO Breast Cancer Guidelines (CSCO BC Guidelines). Among the most notable changes was a revision in the treatment approach for patients with HER2-low breast cancer. Oncology Frontier invited Professor Ying Yan from Beijing Cancer Hospital to provide insights into the new treatment strategies for HER2-low and HER2 ultra-low breast cancer.
NCCN 2025 | Professor Jihong Liu: Strengthening Management and Monitoring Adverse Events in Immunotherapy-Chemotherapy for Endometrial Cancer

NCCN 2025 | Professor Jihong Liu: Strengthening Management and Monitoring Adverse Events in Immunotherapy-Chemotherapy for Endometrial Cancer

Endometrial cancer is one of the most common gynecologic malignancies, with its global incidence on the rise. In recent years, immunotherapy combined with chemotherapy has emerged as a promising strategy, demonstrating significant benefits in prolonging survival and maintaining durable responses in patients with advanced or recurrent endometrial cancer. However, as the use of immuno-chemotherapy becomes more widespread, concerns surrounding its safety profile have also come to the forefront.
ELCC 2025 | Professor Keith Kerr Receives the Heine H. Hansen Award

ELCC 2025 | Professor Keith Kerr Receives the Heine H. Hansen Award

At the European Lung Cancer Congress (ELCC), the prestigious Heine H. Hansen Award was presented to Professor Keith Kerr, a pathologist from the Aberdeen Royal Infirmary, in recognition of his outstanding contributions to oncology research. The announcement was made by ELCC co-chairs Professor Enrico Ruffini, a thoracic surgeon from the Università di Torino, and Professor Myung-Ju Ahn, a medical oncologist from Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul/KR
ELCC Co-Chair, Professor Enrico Ruffini Highlights Key Differences in Surgical Management Strategies for Thymoma and Thymic Carcinoma

ELCC Co-Chair, Professor Enrico Ruffini Highlights Key Differences in Surgical Management Strategies for Thymoma and Thymic Carcinoma

At the 2025 European Lung Cancer Congress (ELCC), Professor Enrico Ruffini, thoracic surgeon at the Università di Torino and Co-Chair of the ELCC, delivered a dedicated presentation titled "Thymoma and thymic carcinoma: Different surgical management strategies?" During the conference, Oncology Frontier had the opportunity to speak with Professor Ruffini for an in-depth discussion on the latest developments in surgical treatment for thymic tumors and key takeaways from the ELCC.
Prof. Chunfang Hao: Highlights from the Updated CSCO Guidelines for HR+ mBC – A Dual Emphasis on Endocrine Combination Therapy and Precision Testing

Prof. Chunfang Hao: Highlights from the Updated CSCO Guidelines for HR+ mBC – A Dual Emphasis on Endocrine Combination Therapy and Precision Testing

The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, featured the highly anticipated update to the CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer (CSCO BC Guidelines). The latest edition further refines stratified treatment strategies and emphasizes the importance of both precision medicine and combination therapies—providing more detailed and practical guidance for clinicians. To explore the key updates, Oncology Frontier invited Prof. Chunfang Hao from the Tianjin Cancer  Hospital (Airport Hospital) to elaborate on recent advances in the endocrine management of hormone receptor-positive (HR+) metastatic breast cancer (mBC).
In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout

In-Depth Dialogue with the Chief Medical Officer: Defining AI Boundaries, Breaking Through Resource Equity, and Addressing Professional Burnout

As the 2025 Annual Meeting of the National Comprehensive Cancer Network (NCCN) concluded, Oncology Frontier exclusively interviewed Dr. Wui-Jin Koh, Chief Medical Officer of NCCN, to decode the future trends in cancer care. From the application prospects of AI-assisted medical decision-making to the inclusive practice of decentralized clinical trials, from the systemic challenges of combating healthcare professionals' burnout to the ecological reconstruction of cancer patient care systems, Dr. Wui-Jin Koh’s insights not only reveal NCCN’s future directions but also provide valuable references for the global medical community.